Osiris Therapeutics, Inc. (OSIR) Announces Receipt Of $15 Million Cash Payment For Prochymal
4/9/2014 9:26:04 AM
COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell company focused on developing and marketing products to treat conditions in wound care, orthopedic and sports medicine markets, announced that it has received the next $15 million cash payment from Mesoblast in accordance with the Purchase Agreement relating to the Prochymal business.
Help employers find you! Check out all the jobs and post your resume.
comments powered by